{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:02:14Z","timestamp":1782975734256,"version":"3.54.5"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pain Res."],"abstract":"<jats:p>\n                    Fibromyalgia is a chronic pain disorder with multiple proposed etiologies. Pharmacological treatments approved for fibromyalgia are few and not always effective; therefore, some practitioners use off-label medications such as low dose naltrexone (LDN). This case series presents a retrospective chart review of patients who were prescribed LDN for fibromyalgia at an integrative medicine clinic over a 2-year period. Outcomes assessed included pain relief, other health benefits, side effects and prescription habits. Of 10 patients identified, LDN provided substantial pain relief for 8 patients (\u22124.7\/10 points, average \u22123.75\/10 for all 10 patients,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&amp;lt;\u20090.001). These same patients also reported other important health benefits such better quality of life in 6 patients, reductions in pain flares in 5 patients, improved sleep in 4 patients, improved cognitive functioning in 2 patients, and cessation of other pain medications in 4 patients. Two patients discontinued LDN due to side effects, which in both cases was increased pain. LDN was well tolerated overall, although reported side effects included increased pain, vivid dreams, insomnia and irritability. LDN's proposed mechanism involving hormesis at opioid receptors and its implications for customized dosing in clinical care and research trials are discussed. While not all patients respond to LDN, this medication shows promise as an effective and safe intervention and deserves to be considered as a treatment recommendation for fibromyalgia.\n                  <\/jats:p>","DOI":"10.3389\/fpain.2026.1731455","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:34:05Z","timestamp":1782970445000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Low dose naltrexone for fibromyalgia: case series demonstrating pain relief and other health benefits"],"prefix":"10.3389","volume":"7","author":[{"given":"Adrienne","family":"Junek","sequence":"first","affiliation":[{"name":"Department of Family Medicine, University of Ottawa","place":["Ottawa, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mya","family":"Anderson","sequence":"additional","affiliation":[{"name":"Bachelor of Science Honors, University of Ottawa","place":["Ottawa, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1155\/2013\/918216","article-title":"National fibromyalgia guideline advisory panel 2012 Canadian guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary","volume":"18","author":"Fitzcharles","year":"2013","journal-title":"Pain Res Manag"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e48032","DOI":"10.7759\/cureus.48032","article-title":"Beyond the pain: a systematic narrative review of the latest advancements\u00a0in\u00a0fibromyalgia treatment","volume":"15","author":"Ram","year":"2023","journal-title":"Cureus"},{"key":"B3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1136\/annrheumdis-2016-209724","article-title":"EULAR Revised recommendations for the management of fibromyalgia","volume":"76","author":"Macfarlane","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e81086","DOI":"10.7759\/cureus.81086","article-title":"Therapeutic uses and efficacy of low-dose naltrexone: a scoping review","volume":"17","author":"Leiber","year":"2025","journal-title":"Cureus"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.2023.19761","article-title":"Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis","volume":"330","author":"McPheeters","year":"2023","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.2147\/JPR.S451183","article-title":"Effective doses of low-dose naltrexone for chronic pain\u2014an observational study","volume":"17","author":"Marcus","year":"2024","journal-title":"J Pain Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/medsci6040082","article-title":"Low-dose naltrexone (LDN)-review of therapeutic utilization","volume":"6","author":"Toljan","year":"2018","journal-title":"Med Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.neuroscience.2004.08.029","article-title":"Ultra-low dose naltrexone potentiates the anticonvulsant effect of low dose morphine on clonic seizures","volume":"129","author":"Honar","year":"2004","journal-title":"Neuroscience"},{"key":"B9","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/bph.13394","article-title":"Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4","volume":"173","author":"Wang","year":"2016","journal-title":"Br J Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11916-020-00898-0","article-title":"Low-dose naltrexone for chronic pain: update and systemic\u00a0review","volume":"24","author":"Kim","year":"2020","journal-title":"Curr Pain Headache Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"100707","DOI":"10.1016\/j.bbih.2023.100707","article-title":"Altered response to toll-like receptor 4 activation in fibromyalgia: a low-dose, human experimental endotoxemia pilot study","volume":"34","author":"Jones","year":"2023","journal-title":"Brain Behav Immun Health"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s10787-023-01216-x","article-title":"Microglia polarization in nociplastic pain: mechanisms and perspectives","volume":"31","author":"Atta","year":"2023","journal-title":"Inflammopharmacology"},{"key":"B13","first-page":"406","article-title":"Naltrexone","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver\u00a0Injury","year":"2012"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1002\/hep4.2080","article-title":"Naltrexone for alcohol use disorder: hepatic safety in patients with and without liver disease","volume":"6","author":"Ayyala","year":"2022","journal-title":"Hepatol Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1097\/MS9.0000000000003203","article-title":"Efficacy and safety of low-dose naltrexone (LDN) in fibromyalgia: a systematic review and meta-analysis","volume":"87","author":"Nazir","year":"2025","journal-title":"Ann Med Surg"},{"key":"B16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3344\/kjp.24202","article-title":"Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis","volume":"37","author":"Vatvani","year":"2024","journal-title":"Korean J Pain"},{"key":"B17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/j.1526-4637.2009.00613.x","article-title":"Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study","volume":"10","author":"Younger","year":"2009","journal-title":"Pain Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/art.37734","article-title":"Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels","volume":"65","author":"Younger","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B19","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1080\/15360288.2024.2358941","article-title":"A utilization review of patients that respond to low-dose naltrexone (LDN) for chronic pain at a single institution","volume":"38","author":"Pogue","year":"2024","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3390\/biomedicines11041087","article-title":"Efficacy of low-dose naltrexone and predictors of treatment success or discontinuation in fibromyalgia and other chronic pain conditions: a fourteen-year, enterprise-wide retrospective analysis","volume":"11","author":"Driver","year":"2023","journal-title":"Biomedicines"},{"key":"B21","first-page":"1","article-title":"Efficacy of low-dose naltrexone in treating patients with fibromyalgia: systematic review and meta-analysis","volume":"24","author":"Cai","year":"2025","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"B22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/15360288.2024.2302550","article-title":"Efficacy and safety of low dose naltrexone for chronic pain","volume":"38","author":"N. Irwin","year":"2024","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"B23","first-page":"441","article-title":"Low-dose naltrexone as first option for fibromyalgia patients: a case series","volume":"26","author":"Freire de Carvalho","year":"2024","journal-title":"Isr Med Assoc J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e1080","DOI":"10.1097\/PR9.0000000000001080","article-title":"Low-dose naltrexone for treatment of pain in patients with fibromyalgia: a randomized, double-blind, placebo-controlled, crossover study","volume":"8","author":"Bested","year":"2023","journal-title":"Pain Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/S2665-9913(23)00278-3","article-title":"Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial","volume":"6","author":"Due Bruun","year":"2024","journal-title":"Lancet Rheumatoid"},{"key":"B26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2174\/0115733971274700231226075717","article-title":"Diet and lifestyle modifications for fibromyalgia","volume":"20","author":"Metyas","year":"2024","journal-title":"Curr Rheumatol Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.neuron.2025.03.032","article-title":"The gut microbiota promotes pain in fibromyalgia","volume":"113","author":"Cai","year":"2025","journal-title":"Neuron"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1253121","DOI":"10.3389\/fimmu.2023.1253121","article-title":"Increased gut permeability and bacterial translocation are associated with fibromyalgia and myalgic encephalomyelitis\/chronic fatigue syndrome: implications for disease-related biomarker discovery","volume":"14","author":"Mart\u00edn","year":"2023","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/01.ajp.0000149796.08746.ea","article-title":"Sexual and physical abuse in women with fibromyalgia syndrome: a test of the trauma hypothesis","volume":"21","author":"Ciccone","year":"2005","journal-title":"Clin J Pain"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2114451","DOI":"10.1155\/2022\/2114451","article-title":"Prevalence and characterization of psychological trauma in patients with fibromyalgia: a cross-sectional study","volume":"2022","author":"Gardoki-Souto","year":"2022","journal-title":"Pain Res Manag"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1080\/09602011.2024.2314883","article-title":"The effect of eye movement desensitization and reprocessing on fibromyalgia: a multiple-baseline experimental case study across ten participants","volume":"34","author":"Borst","year":"2024","journal-title":"Neuropsychol Rehabil"},{"key":"B32","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1037\/tra0000635","article-title":"Integrated intervention for comorbid posttraumatic stress disorder and fibromyalgia: a pilot study of women veterans","volume":"12","author":"Lacefield","year":"2020","journal-title":"Psychol Trauma"},{"key":"B33","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3390\/biomedicines10050953","article-title":"Neuroinflammation in post-traumatic stress disorder","volume":"10","author":"Lee","year":"2022","journal-title":"Biomedicines"},{"key":"B34","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/acr.23731","article-title":"Diagnosis of fibromyalgia: disagreement between fibromyalgia criteria and clinician-based fibromyalgia diagnosis in a university clinic","volume":"71","author":"Wolfe","year":"2019","journal-title":"Arthritis Care Res"},{"key":"B35","first-page":"16","article-title":"Chronic pain syndromes: myofascial pain syndrome","volume":"533","author":"Henson","year":"2023","journal-title":"FP Essent"},{"key":"B36","doi-asserted-by":"publisher","first-page":"593842","DOI":"10.3389\/fpsyt.2021.593842","article-title":"The effects of low dose naltrexone on opioid induced hyperalgesia and fibromyalgia","volume":"12","author":"Jackson","year":"2021","journal-title":"Front Psychiatry"},{"key":"B37","first-page":"197","article-title":"Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone","volume":"26","author":"Oaks","year":"2018","journal-title":"Discov Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.2147\/JPR.S389957","article-title":"Low-dose naltrexone (LDN) for chronic pain at a single institution: a case series","volume":"16","author":"McKenzie-Brown","year":"2023","journal-title":"J Pain Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.clinthera.2023.03.013","article-title":"Pilot study of low-dose naltrexone for the treatment of chronic pain due to arthritis: a randomized, double-blind, placebo-controlled, crossover clinical trial","volume":"45","author":"Beaudette-Zlatanova","year":"2023","journal-title":"Clin Ther"}],"container-title":["Frontiers in Pain Research"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2026.1731455\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:34:07Z","timestamp":1782970447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2026.1731455\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":39,"alternative-id":["10.3389\/fpain.2026.1731455"],"URL":"https:\/\/doi.org\/10.3389\/fpain.2026.1731455","relation":{},"ISSN":["2673-561X"],"issn-type":[{"value":"2673-561X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"article-number":"1731455"}}